Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical ...

Auditing pharmaceutical supply chains down to every last employee and pallet would be ideal, but is logistically impractical.

With the rise in global counterfeiting operations, stakeholders need to be aware of their responsibility when it comes to pharmaceutical goods and their legitimacy. Companies can make this task easier ...

For over 30 years, the US has clung to an outdated and misguided war on testosterone, lumping it in with the anabolic ...

Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

NHS Wales has signed a memorandum of understanding (MoU) with Illumina to expand an earlier partnership focusing on lung ...

That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health ...

Data – it’s everywhere! Especially in clinical trials, where an average trial of about 2,000 patients can expect to produce 3,000,000 points of data across labs, vitals, medications, and ...

After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved swiftly to shore up its finances with a $225 million second round to fund the development of ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...